Sunil Sagi is a notable inventor based in Fountainville, PA (US). He has made significant contributions to the field of pharmaceutical compositions, particularly focusing on nucleotide analogues. His work has implications for the treatment of various diseases, including viral infections and cancer.

Latest Patents

Sunil Sagi holds a patent for "Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs." This patent discloses highly stable compositions that exhibit outstanding storage stability and exceptional resistance to degradation in aqueous solutions. The compositions include orally active nucleotide analogs or prodrugs, such as adefovir dipivoxil and tenofovir disoproxil. Notably, when stored under specific conditions, these compositions maintain a low level of less orally bioavailable impurities, ensuring their effectiveness.

Career Highlights

Sunil Sagi is currently associated with Sigmapharm Laboratories, LLC, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing stable and effective treatments for patients.

Collaborations

Sunil collaborates with Ishari Piya, contributing to advancements in their field through shared expertise and innovative ideas.

Conclusion

Sunil Sagi's contributions to the development of stable nucleotide analogues highlight his role as a key inventor in the pharmaceutical industry. His work not only advances scientific knowledge but also has the potential to improve patient outcomes in the treatment of serious diseases.

Profile summary based on public USPTO records.